Plasma Fractionation Market Outlook:
Plasma derived immunoglobulins are being increasingly used in multiple clinical indications such as autoimmune and inflammatory diseases. The plasma fractionation market has heavily invested in therapies such as Ceruloplasmin, IgA and Plasmin. In addition, burgeoning investments in innovation and technological advancements in efficient and cost-effective procedures for fractioning proteins shall give impetus to the market.
On the back of the aforementioned trends, the global plasma fractionation market is poised to experience an uptick in the forecast period (2020-2026). Anticipated CAGR for the market is pegged at a staggering 7.1%. The COVID-19 pandemic is anticipated to generate potential growth opportunities for the plasma fractionation market. This is attributed to the efforts by key players to collaborate on convalescent plasma (CP) extraction and study its effects on COVID-19 patients.
Plasma Fractionation Market Share Analysis by Application:
The neurology segment is anticipated to enjoy the lion’s share of the plasma fractionation market. A spurt in neurological disorders is responsible for the growing scope of the neurology segment. Fact.MR projects that neurological disorders plague more than 450 million people globally. The neurology segment shall account for more than two-fifths of the plasma fractionation market, leveraging at a CAGR of 7.2%.
Trailing behind is the immunology segment, expanding 1.5x during the forecast period. Rising popularity of immunoglobulins as an important treatment option for autoimmune and inflammatory diseases is anticipated to be a key growth driver. The immunology segment is anticipated to capture almost one-third of the plasma fractionation market, reaching a value of US$ 10 Bn by the end of 2026.
To get the latest COVID-19 impact insights on the plasma fractionation market, ask an analyst here
Plasma Fractionation Market Analysis by Region:
The North American plasma fractionation market shall lay suzerainty during the forecast period. The North American region is set to capture nearly 2/5th of the plasma fractionation market, expanding at a CAGR of 6.6%. A robust healthcare sector along with continuous technological innovation shall accelerate demand for plasma fractionation in North America. Moreover, the prevalence of neurological and autoimmune diseases as well as hemophilia shall boost demand prospects for plasma fractionation.
Asia-Pacific shows a promising outlook for the growth of the plasma fractionation market. Therapeutic applicability of plasma fractionation proteins is an important growth lever for the Asia-Pacific market. Moreover, technological improvements in healthcare sectors of emerging economies are anticipated to pave way for exciting market prospects during the forecast period. Projected CAGR for the Asia-Pacific market is pegged at a staggering 8.0%. Also, prevalence of immune and bleeding disorders have prompted investments in plasma fractionation techniques.
Access our exhaustive repertoire of in-depth regional insights on the plasma fractionation market by requesting for a report sample here
Plasma Fractionation Companies: Nuanced Research Trump Card for Key Players
The plasma fractionation market consists of multiple players. These are: CSL Behring, Shire plc, Sanquin, Biotest AG, GRIFOLS, Baxter International Inc., Kedrion, Octapharma USA Inc. to name a few. Innovative product offerings and new product development are key growth strategies adopted by market players.
CSL Behring, for instance, markets the Privigen, Carimune, Snadoglobulin and Hizentra solutions. Sanquin produces four types of plasma products using various isolation techniques: coagulation factors, protease inhibitors, immunoglobulins and albumin. The company also offers contract fractionation services.
Biotest AG develops, manufactures and markets plasma proteins and biotherapeutic drugs. It leads in the field of plasma collection. Biotest AG presently develops plasma proteins for Primary Immune Deficiency (PID) and various hyperimmune products. Examples of the products offered are Varitect, Cytotect CP and Albiomin.
COVID-19 Market Insights:
The COVID-19 pandemic is set to offer significant growth opportunities for the plasma fractionation market. Several countries are experimenting with plasma fractionation techniques to find potential cures and diagnostic methodologies for the novel coronavirus. A potential method of curing COVID-19 positive patients is the usage of convalescent plasma (CP). The plasma is extracted from the blood of a formerly infected person and then administered to an existing patient. The patient therefore acquires passive immunization as the plasma is said to contain critical antibodies to fight the virus.
Octapharma, a leading pharmaceutical company, is putting its expertise to work to find new treatments for COVID-19. It is doing so by collaborating with leading plasma fractionation players in order to develop a potential plasma-derived hyperimmune immunoglobulin therapy. The alliance is investigating the development of one unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine. The medicine has the potential to treat patients with severe COVID-19 symptoms. The alliance includes companies such as CSL Behring, Takeda BPL, Biotest and LFB.
Likewise, Grifols has entered into a formal collaboration with the United States Biomedical Advanced Research Department Authority (BARDA), the FDA and other federal public health authorities. The company is collecting convalescent plasma to support the necessary preclinical and clinical studies to determine if the anti-SARS-CoV-2 hyperimmune immunoglobulin is effective to treat COVID-19.
Analyst’s Viewpoint:
The plasma fractionation market is poised to embark on a positive growth trajectory. Rising technological innovation and augmenting demand for plasma proteins are credited as important growth drivers. Moreover, the COVID-19 pandemic has prompted market players to invest in developing plasma-based solutions to eradicate the disease. Regionally, North America is poised to retain market hegemony while Asia-Pacific promises attractive growth opportunities.
Plasma Fractionation Market: Report Scope:
The recent study by Fact.MR on plasma fractionation incorporates a six-year forecast period, elucidating on the potential drivers, opportunities and restraints across key segments and regions. The plasma fractionation market has been segmented on the basis of product type, application and end-users. Each segment contains a detailed analysis of their market share and revenue.
A detailed regional analysis for five geographies has been embedded in the report. These regions are North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA). Each region includes the segmental analysis highlighted above. In addition, a competition landscape has also been included. This section provides details about the key market players, their revenue, and their strategies for expansion and product launches. Moreover, a SWOT analysis has been provided to provide a realistic picture for future prospects of the market players.
Plasma Fractionation Market- Scope of the Report
The recent study by Fact.MR on plasma fractionation market offers a 6-year forecast between 2020 and 2026. The study analyzes crucial trends that are currently determining the growth of the plasma fractionation market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders and emerging players associated with the provision of plasma fractionation services. The study also provides dynamics that are responsible for influencing the future status of the plasma fractionation market over the forecast period.
A detailed assessment of the plasma fractionation market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the plasma fractionation market along with their product portfolio enhances the reliability of this comprehensive research study.
Plasma Fractionation Market: Report Summary
The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in the plasma fractionation market across the globe.
A comprehensive estimate on the plasma fractionation market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of plasma fractionation market during the forecast period.
Plasma Fractionation Market Segmentation
Fact.MR has studied the plasma fractionation market with detailed segmentation on the basis of product, application, end-user and region.
|
Product |
Application |
End-user |
Region |
|
Immunoglobulins:
|
Neurology |
Hospitals & Clinics |
North America |
|
Coagulation Factor Concentrates:
|
Immunology |
Clinical Research Laboratories |
Europe |
|
Albumin |
Hematology |
Academic Institutions |
Asia Pacific |
|
Protease Inhibitors |
Critical Care |
|
Latin America |
|
Other Plasma Products |
Pulmonary |
|
Middle East & Africa |
|
|
Other Applications |
|
|
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”
Plasma Fractionation Market: Analysis on Market Size Evaluation
The plasma fractionation market has been analyzed for each market segment, in terms of value (US$ Mn).
Market estimates at global and regional levels for Plasma fractionation market is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent plasma fractionation market segments, along with market attractiveness evaluation has been incorporated in the report.
Plasma Fractionation Market: Inspected Assessment on Regional Segments
Key sections have been elaborated in the plasma fractionation report, which have helped deliver projection on the regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of the plasma fractionation market during the forecast period.
Country-specific valuation on demand for plasma fractionation has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value for emerging countries has also been included in the report.
Plasma Fractionation Market: In-Depth Analysis on Competitive Landscape
The report sheds light on the leading manufacturers of plasma fractionation products along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of plasma fractionation products, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, such as product portfolio, key strategies along with an all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the plasma fractionation market. Prominent manufacturers with established market presence in global Plasma fractionation market are GRIFOLS, Sanquin, CSL Behring Limited, Shire Plc., Biotest AG, Baxter International, etc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Plasma Fractionation Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Plasma Fractionation Market Analysis and Forecast, 2020–2026
5. Market Outlook
5.1. Regional Distribution of Fractionation Plants
5.2. Regional Distribution of Fractionation Throughput
5.3. Worldwide IVIG Unit Sales by Region
5.4. Worldwide Albumin Unit Sales by Region
5.5. Plasma Proteins and their Clinical Significance
5.6. Value Chain Analysis
6. Global Plasma Fractionation Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026
6.3.1. Immunoglobulin
6.3.1.1. Intravenous Immunoglobulin
6.3.1.2. Subcutaneous Immunoglobulin
6.3.2. Coagulation Factor Concentrates
6.3.2.1. Factor VIII
6.3.2.2. Factor IX
6.3.2.3. Factor XIII
6.3.2.4. Prothrombin Complex Concentrates
6.3.2.5. Von Willebrand Factor (VWF)
6.3.2.6. Fibrinogen Concentrates
6.3.3. Albumin
6.3.4. Protease Inhibitors
6.3.5. Other Plasma Products
6.4. Global Plasma Fractionation Market Attractiveness, by Product Type
7. Global Plasma Fractionation Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Global Plasma Fractionation Market Value Forecast, by Application, 2020–2026
7.2.1. Neurology
7.2.2. Immunology
7.2.3. Hematology
7.2.4. Critical Care
7.2.5. Pulmonology
7.2.6. Other Applications
7.7. Global Plasma Fractionation Market Attractiveness, by Product
8. Global Plasma Fractionation Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Global Plasma Fractionation Market Value Forecast, by End-user, 2020–2026
8.2.1. Hospitals and Clinics
8.2.2. Clinical Research Laboratories
8.2.3. Academic Institutes
9. Global Plasma Fractionation Market Analysis and Forecast, by Region
9.1. Global Market Scenario
9.2. Global Plasma Fractionation Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Plasma Fractionation Market Attractiveness, by Region
10. North America Plasma Fractionation Market Analysis and Forecast
10.1. Introduction
10.2. North America Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026
10.2.1. Immunoglobulin
10.2.1.1. Intravenous Immunoglobulin
10.2.1.2. Subcutaneous Immunoglobulin
10.2.2. Coagulation Factor Concentrates
10.2.2.1. Factor VIII
10.2.2.2. Factor IX
10.2.2.3. Factor XIII
10.2.2.4. Prothrombin Complex Concentrates
10.2.2.5. Von Willebrand Factor (VWF)
10.2.2.6. Fibrinogen Concentrates
10.2.3. Albumin
10.2.4. Protease Inhibitors
10.2.5. Other Plasma Products
10.3. North America Plasma Fractionation Market Value Forecast, by Application, 2020–2026
10.3.1. Neurology
10.3.2. Immunology
10.3.3. Hematology
10.3.4. Critical Care
10.3.5. Pulmonology
10.3.6. Other Applications
10.4. North America Plasma Fractionation Market Value Forecast, by End-user, 2020–2026
10.4.1. Hospitals and Clinics
10.4.2. Clinical Research Laboratories
10.4.3. Academic Institutes
10.5. North America Plasma Fractionation Market Value Forecast, by Country, 2020–2026
10.5.1. U.S.
10.5.2. Canada
10.6. North America Plasma Fractionation Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By End-user
10.6.4. Country
11. Europe Plasma Fractionation Market Analysis and Forecast
11.1. Introduction
11.2. Europe Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026
11.2.1. Immunoglobulin
11.2.1.1. Intravenous Immunoglobulin
11.2.1.2. Subcutaneous Immunoglobulin
11.2.2. Coagulation Factor Concentrates
11.2.2.1. Factor VIII
11.2.2.2. Factor IX
11.2.2.3. Factor XIII
11.2.2.4. Prothrombin Complex Concentrates
11.2.2.5. Von Willebrand Factor (VWF)
11.2.2.6. Fibrinogen Concentrates
11.2.3. Albumin
11.2.4. Protease Inhibitors
11.2.5. Other Plasma Products
11.3. Europe Plasma Fractionation Market Value Forecast, by Application, 2020–2026
11.3.1. Neurology
11.3.2. Immunology
11.3.3. Hematology
11.3.4. Critical Care
11.3.5. Pulmonology
11.3.6. Other Applications
11.4. Europe Plasma Fractionation Market Value Forecast, by End-user, 2020–2026
11.4.1. Hospitals and Clinics
11.4.2. Clinical Research Laboratories
11.4.3. Academic Institutes
11.5. Europe Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2020–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Plasma Fractionation Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By End-user
11.6.4. Country
12. Asia Pacific Plasma Fractionation Market Analysis and Forecast
12.1. Introduction
12.2. Asia Pacific Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026
12.2.1. Immunoglobulin
12.2.1.1. Intravenous Immunoglobulin
12.2.1.2. Subcutaneous Immunoglobulin
12.2.2. Coagulation Factor Concentrates
12.2.2.1. Factor VIII
12.2.2.2. Factor IX
12.2.2.3. Factor XIII
12.2.2.4. Prothrombin Complex Concentrates
12.2.2.5. Von Willebrand Factor (VWF)
12.2.2.6. Fibrinogen Concentrates
12.2.3. Albumin
12.2.4. Protease Inhibitors
12.2.5. Other Plasma Products
12.3. Asia Pacific Plasma Fractionation Market Value Forecast, by Application, 2020–2026
12.3.1. Neurology
12.3.2. Immunology
12.3.3. Hematology
12.3.4. Critical Care
12.3.5. Pulmonology
12.3.6. Other Applications
12.4. Asia Pacific Plasma Fractionation Market Value Forecast, by End-user, 2020–2026
12.4.1. Hospitals and Clinics
12.4.2. Clinical Research Laboratories
12.4.3. Academic Institutes
12.5. Asia Pacific Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2020–2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Plasma Fractionation Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By End-user
12.6.4. Country
13. Latin America Plasma Fractionation Market Analysis and Forecast
13.1. Introduction
13.2. Latin America Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026
13.2.1. Immunoglobulin
13.2.1.1. Intravenous Immunoglobulin
13.2.1.2. Subcutaneous Immunoglobulin
13.2.2. Coagulation Factor Concentrates
13.2.2.1. Factor VIII
13.2.2.2. Factor IX
13.2.2.3. Factor XIII
13.2.2.4. Prothrombin Complex Concentrates
13.2.2.5. Von Willebrand Factor (VWF)
13.2.2.6. Fibrinogen Concentrates
13.2.3. Albumin
13.2.4. Protease Inhibitors
13.2.5. Other Plasma Products
13.3. Latin America Plasma Fractionation Market Value Forecast, by Application, 2020–2026
13.3.1. Neurology
13.3.2. Immunology
13.3.3. Hematology
13.3.4. Critical Care
13.3.5. Pulmonology
13.3.6. Other Applications
13.4. Latin America Plasma Fractionation Market Value Forecast, by End-user, 2020–2026
13.4.1. Hospitals and Clinics
13.4.2. Clinical Research Laboratories
13.4.3. Academic Institutes
13.5. Latin America Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2020–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Plasma Fractionation Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By End-user
13.6.4. Country
14. Middle East & Africa Plasma Fractionation Market Analysis and Forecast
14.1. Introduction
14.2. Middle East & Africa Plasma Fractionation Market Value Forecast, by Product Type, 2020–2026
14.2.1. Immunoglobulin
14.2.1.1. Intravenous Immunoglobulin
14.2.1.2. Subcutaneous Immunoglobulin
14.2.2. Coagulation Factor Concentrates
14.2.2.1. Factor VIII
14.2.2.2. Factor IX
14.2.2.3. Factor XIII
14.2.2.4. Prothrombin Complex Concentrates
14.2.2.5. Von Willebrand Factor (VWF)
14.2.2.6. Fibrinogen Concentrates
14.2.3. Albumin
14.2.4. Protease Inhibitors
14.2.5. Other Plasma Products
14.3. Middle East & Africa Plasma Fractionation Market Value Forecast, by Application, 2020–2026
14.3.1. Neurology
14.3.2. Immunology
14.3.3. Hematology
14.3.4. Critical Care
14.3.5. Pulmonology
14.3.6. Other Applications
14.4. Middle East & Africa Plasma Fractionation Market Value Forecast, by End-user, 2020–2026
14.4.1. Hospitals and Clinics
14.4.2. Clinical Research Laboratories
14.4.3. Academic Institutes
14.5. Middle East & Africa Plasma Fractionation Market Value Forecast, by Country/Sub-region, 2020–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Plasma Fractionation Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Application
14.6.3. By End-user
14.6.4. Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Company Profiles
15.2.1. CSL Limited
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Shire plc
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Sanquin
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Biotest AG.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. GRIFOLS
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Baxter International Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Kedrion
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Octapharma
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. China Biologic Products Holdings, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
Fact.MR offers custom research services that help clients to get specific research solutions
Related reports
We are committed towards customer satisfaction and quality service.
Our Clients
Fact.MR in Media
Our analysts in Media
Plasma Fractionation Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026